Top

Published in:

01-12-2015 | Epidemiology and Pathophysiology (J Cauley and B Dawson-Hughes, Section Editors)

Bone Density Screening and Re-screening in Postmenopausal Women and Older Men

Authors: Margaret L. Gourlay, Robert A. Overman, Kristine E. Ensrud

Published in: Current Osteoporosis Reports | Issue 6/2015

Abstract

Clinical practice guidelines universally recommend bone mineral density (BMD) screening to identify osteoporosis in women aged 65 years and older. Risk assessment is recommended to guide BMD screening in postmenopausal women under age 65. Insufficient data are available to inform standard ages to start and stop BMD screening in postmenopausal women. Based on longitudinal studies of incident osteoporosis and fracture in postmenopausal women, an initial BMD test should be ordered for all women aged 65, and the frequency of re-screening should be based on age and BMD T score (more frequent testing for older age and lower T score). Although clinical practice guidelines recommend BMD screening according to risk factors for fracture in postmenopausal women under age 65, no standard approach to risk assessment exists. Minimal evidence is available to guide osteoporosis screening in men, but some experts recommend initiation of BMD screening in men at age 70.

Sackett D, Straus S, Richardson W, Rosenberg W, Haynes R. Diagnosis and screening. Evidence-based medicine: how to practice and teach EBM. 2nd ed. New York: Harcourt; 2000. p. 261.

Gourlay ML, Preisser JS, Lui LY, Cauley JA, Ensrud KE. BMD screening in older women: initial measurement and testing interval. J Bone Mineral Res Off J Am Soc Bone Mineral Res. 2012;27(4):743–6. doi:10.1002/jbmr.1585.CrossRef

Burge R, Dawson-Hughes B, Solomon D, Wong J, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22:465–75.CrossRefPubMed

Mackey DC, Black DM, Bauer DC, McCloskey EV, Eastell R, Mesenbrink P, et al. Effects of antiresorptive treatment on nonvertebral fracture outcomes. J Bone Miner Res. 2011;26(10):2411–8. doi:10.1002/jbmr.446.CrossRefPubMed

Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2005;16 Suppl 2:S3-7. doi:10.1007/s00198-004-1702-6

Sanchez-Riera L, Wilson N, Kamalaraj N, Nolla JM, Kok C, Li Y, et al. Osteoporosis and fragility fractures. Best Pract Res Clin Rheumatol. 2010;24(6):793–810. doi:10.1016/j.berh.2010.10.003.CrossRefPubMed

Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254–9.PubMedCentralCrossRefPubMed

Wainwright SA, Marshall LM, Ensrud KE, Cauley JA, Black DM, Hillier TA, et al. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab. 2005;90(5):2787–93. doi:10.1210/jc.2004-1568.CrossRefPubMed

Stone K, Seeley D, Lui L, Cauley J, Ensrud K, Browner W, et al. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res. 2003;18:1947–54.CrossRefPubMed

10.

Kanis JA, Oden A, Johansson H, Borgstrom F, Strom O, McCloskey E. FRAX and its applications to clinical practice. Bone. 2009;44(5):734–43. doi:10.1016/j.bone.2009.01.373.CrossRefPubMed

11.

Ensrud KE. Epidemiology of fracture risk with advancing age. J Gerontol A Biol Sci Med Sci. 2013;68(10):1236–42. doi:10.1093/gerona/glt092.CrossRefPubMed

12.

Wilks DC, Winwood K, Gilliver SF, Kwiet A, Chatfield M, Michaelis I, et al. Bone mass and geometry of the tibia and the radius of master sprinters, middle and long distance runners, race-walkers and sedentary control participants: a pQCT study. Bone. 2009;45(1):91–7. doi:10.1016/j.bone.2009.03.660.PubMedCentralCrossRefPubMed

13.

Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008;1:CD001155. doi:10.1002/14651858.CD001155.pub2.PubMed

14.

Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008;1:CD004523.PubMed

15.

Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357(18):1799–809. doi:10.1056/NEJMoa074941.CrossRefPubMed

16.

Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282(7):637–45.CrossRefPubMed

17.

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–41. doi:10.1056/NEJM200105103441904.CrossRefPubMed

18.

Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–65. doi:10.1056/NEJMoa0809493.CrossRefPubMed

19.

Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013;8(1-2):136. doi:10.1007/s11657-013-0136-1.PubMedCentralCrossRefPubMed

20.

Watts NB, Leslie WD, Foldes AJ, Miller PD. 2013 International Society for Clinical Densitometry Position Development Conference: Task Force on Normative Databases. J Clin Densitometry Off J Int Soc Clin Densitometry. 2013;16(4):472–81. doi:10.1016/j.jocd.2013.08.001.CrossRef

21.

Richy F, Gourlay ML, Garrett J, Hanson L, Reginster JY. Osteoporosis prevalence in men varies by the normative reference. J Clin Densitom. 2004;7(2):127–33.CrossRefPubMed

22.

Kanis JA, McCloskey E, Johansson H, Oden A, Leslie WD. FRAX((R)) with and without bone mineral density. Calcif Tissue Int. 2012;90(1):1–13. doi:10.1007/s00223-011-9544-7.CrossRefPubMed

23.

Siris ES, Adler R, Bilezikian J, Bolognese M, Dawson-Hughes B, Favus MJ et al. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2014;25(5):1439-43. doi:10.1007/s00198-014-2655-z.

24.

Schousboe JT, Ensrud KE. Diagnostic criteria for osteoporosis should not be expanded. Lancet Diabetes Endocrinol. 2015;3(4):236–8. doi:10.1016/S2213-8587(15)00050-9.CrossRefPubMed

25.

Screening for osteoporosis in postmenopausal women: recommendations and rationale. Annals of internal medicine. 2002;137(6):526-8.

26.

Screening for osteoporosis: U.S. preventive services task force recommendation statement. Ann Intern Med. 2011;154(5):356-64. Doi: 10.1059/0003-4819-154-5-201103010-00307.

27.

Crandall CJ, Larson J, Gourlay ML, Donaldson MG, Lacroix A, Cauley JA, et al. Osteoporosis screening in postmenopausal women 50-64 years-old: comparison of U.S. Preventive Services Task Force Strategy and two traditional strategies in the Women's Health Initiative. J Bone Mineral Res Off J Am Soc Bone Mineral Res. 2014. doi:10.1002/jbmr.2174.

28.

Crandall CJ, Larson JC, Watts NB, Gourlay ML, Donaldson MG, LaCroix A, et al. Comparison of fracture risk prediction by the US Preventive Services Task Force strategy and two alternative strategies in women 50-64 years old in the Women's Health Initiative. J Clin Endocrinol Metab. 2014;99(12):4514–22. doi:10.1210/jc.2014-2332.CrossRefPubMed

29.

Looker AC, Melton 3rd LJ, Borrud LG, Shepherd JA. Lumbar spine bone mineral density in US adults: demographic patterns and relationship with femur neck skeletal status. Osteoporos Int. 2012;23(4):1351–60. doi:10.1007/s00198-011-1693-z.CrossRefPubMed

30.

Looker AC, Frenk SM. Percentage of adults aged 65 and over with osteoporosis or low bone mass at the femur neck or lumbar spine: United States, 2005–2010. National Center for Health Statistics. August 2015. Available from: http://www.cdc.gov/nchs/data/hestat/osteoporsis/osteoporosis2005_2010.htm

31.

Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005;20(7):1185–94. doi:10.1359/JBMR.050304.CrossRefPubMed

32.

Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int. 2001;12(5):417–27. doi:10.1007/s001980170112.CrossRefPubMed

33.

Nelson H, Helfand M, Woolf S, Allan J. Screening for postmenopausal osteoporosis: a review of the evidence for the US Preventive Services Task Force. Ann Intern Med. 2002;137:529–41.CrossRefPubMed

34.

Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008;1:CD001155.PubMed

35.

Fleurence RL, Iglesias CP, Johnson JM. The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature. Pharmacoeconomics. 2007;25(11):913–33.CrossRefPubMed

36.

Zaidi M, Turner CH, Canalis E, Pacifici R, Sun L, Iqbal J, et al. Bone loss or lost bone: rationale and recommendations for the diagnosis and treatment of early postmenopausal bone loss. Curr Osteoporos Rep. 2009;7(4):118–26.CrossRefPubMed

37.

Castelo-Branco C, Davila J, Perello MF, Peguero A, Ros C, Martinez-Serrano MJ, et al. Long-term effect of hormone therapy on bone in early menopause: vertebral fractures after 20 years. Climacteric. 2014;17(4):336–41. doi:10.3109/13697137.2013.871511.CrossRefPubMed

38.

Ravn P, Weiss SR, Rodriguez-Portales JA, McClung MR, Wasnich RD, Gilchrist NL, et al. Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group. J Clin Endocrinol Metab. 2000;85(4):1492–7. doi:10.1210/jcem.85.4.6549.PubMed

39.

Ravn P, Bidstrup M, Wasnich RD, Davis JW, McClung MR, Balske A, et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med. 1999;131(12):935–42.CrossRefPubMed

40.

Cummings SR. A 55-year-old woman with osteopenia. JAMA. 2006;296(21):2601–10. doi:10.1001/jama.296.21.2601.CrossRefPubMed

41.

Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144(10):753–61.CrossRefPubMed

42.

Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2008;66(6):1320–1. doi:10.1016/j.joms.2008.01.054. author reply 1-2.CrossRefPubMed

43.

Odvina CV, Levy S, Rao S, Zerwekh JE, Rao DS. Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol (Oxford). 2010;72(2):161–8. doi:10.1111/j.1365-2265.2009.03581.x.CrossRef

44.

Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90(3):1294–301. doi:10.1210/jc.2004-0952.CrossRefPubMed

45.

Banks E, Reeves GK, Beral V, Balkwill A, Liu B, Roddam A. Hip fracture incidence in relation to age, menopausal status, and age at menopause: prospective analysis. PLoS Med. 2009;6(11):e1000181. doi:10.1371/journal.pmed.1000181.PubMedCentralCrossRefPubMed

46.

Runhaar J, Schiphof D, van Meer B, Reijman M, Bierma-Zeinstra SM, Oei EH. How to define subregional osteoarthritis progression using semi-quantitative MRI Osteoarthritis Knee Score (MOAKS). Osteoarthr Cartil. 2014;22(10):1533–6. doi:10.1016/j.joca.2014.06.022.CrossRefPubMed

47.

Baim S, Binkley N, Bilezikian J, Kendler D, Hans D, Lewiecki E, et al. Official Positions of the International Society for Clinical Densitometry and Executive Summary of the 2007 ISCD Position Development Conference. J Clin Densitom. 2008;11:75–91.CrossRefPubMed

48.

Nelson H, Haney E, Dana T, Bougatsos C, Chou R. Screening for osteoporosis: an update for the U.S. Preventive Services Task Force. Ann Intern Med. 2010;153:1–13.CrossRef

49.

Schousboe JT, Gourlay ML. Comparative effectiveness and cost-effectiveness of strategies to screen for osteoporosis in postmenopausal women. Ann Intern Med. 2011;155(11):788–9. doi:10.1059/0003-4819-155-11-201112060-00012.CrossRefPubMed

50.

Gourlay ML, Overman RA, Fine JP, Ensrud KE, Crandall CJ, Gass ML, et al. Baseline age and time to major fracture in younger postmenopausal women. Menopause. 2014. doi:10.1097/GME.0000000000000356.

51.

Overman RA, Farley JF, Curtis JR, Zhang J, Gourlay ML, Deal CL. DXA utilization between 2006 and 2012 in commercially insured younger postmenopausal women. J Clin Densitometry Off J Int Soc Clin Densitometry. 2015;18(2):145–9. doi:10.1016/j.jocd.2015.01.005.CrossRef

52.

Zhang J, Delzell E, Zhao H, Laster AJ, Saag KG, Kilgore ML, et al. Central DXA utilization shifts from office-based to hospital-based settings among medicare beneficiaries in the wake of reimbursement changes. J Bone Mineral Res Off J Am Soc Bone Mineral Res. 2012;27(4):858–64. doi:10.1002/jbmr.1534.CrossRef

53.

Bonnick S, Johnston CJ, Kleerekoper M, Lindsay R, Miller P, Sherwood L, et al. Importance of precision in bone density measurements. J Clin Densitom. 2001;4:105–10.CrossRefPubMed

54.

Hillier T, Stone K, Bauer D, Rizzo J, Pedula K, Cauley J, et al. Evaluating the value of repeat bone mineral density measurement and prediction of fractures in older women. Arch Intern Med. 2007;167:155–60.CrossRefPubMed

55.

Frost S, Nguyen N, Center J, Eisman J, Nguyen T. Timing of repeat BMD measurements: development of an absolute risk-based prognostic model. J Bone Miner Res. 2009;24:1800–7.CrossRefPubMed

56.••

Gourlay ML, Fine JP, Preisser JS, May RC, Li C, Lui LY, et al. Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med. 2012;366(3):225–33. doi:10.1056/NEJMoa1107142. This competing risk analysis estimated the time to incident osteoporosis by BMD criteria for women aged 67 and older followed for up to 15 years in the Study of Osteoporotic Fractures. The time for 10% of women with baseline T-scores > -1.50 to transition to osteoporosis was approximately 17 years. The corresponding time intervals for women with baseline T-scores -1.50 to -1.99 and -2.00 to -2.49 were 5 years and 1 year respectively.PubMedCentralCrossRefPubMed

57.

Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures Fracture Intervention Trial Research Group. Lancet. 1996;348(9041):1535–41.CrossRefPubMed

58.

McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344(5):333–40. doi:10.1056/NEJM200102013440503.CrossRefPubMed

59.

Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002;23(4):570–8.CrossRefPubMed

60.

Schott A, Ganne C, Hans D, Monnier G, Gauchoux R, Krieg M, et al. Which screening strategy using BMD measurements would be most cost effective for hip fracture prevention in elderly women? A decision analysis based on a Markov model. Osteoporos Int. 2007;18:143–51.CrossRefPubMed

61.

De Laet CE, Van Hout BA, Burger H, Weel AE, Hofman A, Pols HA. Hip fracture prediction in elderly men and women: validation in the Rotterdam study. J Bone Miner Res. 1998;13(10):1587–93. doi:10.1359/jbmr.1998.13.10.1587.CrossRefPubMed

62.

Cummings SR, Cawthon PM, Ensrud KE, Cauley JA, Fink HA, Orwoll ES. BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women. J Bone Miner Res. 2006;21(10):1550–6. doi:10.1359/jbmr.060708.CrossRefPubMed

63.

Berger C, Langsetmo L, Joseph L, Hanley DA, Davison KS, Josse R, et al. Change in bone mineral density as a function of age in women and men and association with the use of antiresorptive agents. CMAJ. 2008;178(13):1660–8. doi:10.1503/cmaj.071416.PubMedCentralCrossRefPubMed

64.

Bass E, French DD, Bradham DD, Rubenstein LZ. Risk-adjusted mortality rates of elderly veterans with hip fractures. Ann Epidemiol. 2007;17(7):514–9. doi:10.1016/j.annepidem.2006.12.004.CrossRefPubMed

65.

von Friesendorff M, McGuigan FE, Besjakov J, Akesson K. Hip fracture in men-survival and subsequent fractures: a cohort study with 22-year follow-up. J Am Geriatr Soc. 2011;59(5):806–13. doi:10.1111/j.1532-5415.2011.03399.x.CrossRef

66.

Haentjens P, Magaziner J, Colon-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, et al. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med. 2010;152(6):380–90. doi:10.1059/0003-4819-152-6-201003160-00008.PubMedCentralCrossRefPubMed

67.

Morin S, Lix LM, Azimaee M, Metge C, Caetano P, Leslie WD. Mortality rates after incident non-traumatic fractures in older men and women. Osteoporos Int. 2011;22(9):2439–48. doi:10.1007/s00198-010-1480-2.CrossRefPubMed

68.

Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA. 2009;301(5):513–21. doi:10.1001/jama.2009.50.CrossRefPubMed

69.

Robbins JA, Biggs ML, Cauley J. Adjusted mortality after hip fracture: From the cardiovascular health study. J Am Geriatr Soc. 2006;54(12):1885–91. doi:10.1111/j.1532-5415.2006.00985.x.CrossRefPubMed

70.

Forsen L, Sogaard AJ, Meyer HE, Edna T, Kopjar B. Survival after hip fracture: short- and long-term excess mortality according to age and gender. Osteoporos Int. 1999;10(1):73–8.CrossRefPubMed

71.

Jacobsen SJ, Goldberg J, Miles TP, Brody JA, Stiers W, Rimm AA. Race and sex differences in mortality following fracture of the hip. Am J Public Health. 1992;82(8):1147–50.PubMedCentralCrossRefPubMed

72.

Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343(9):604–10. doi:10.1056/NEJM200008313430902.CrossRefPubMed

73.

Ringe JD, Faber H, Dorst A. Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab. 2001;86(11):5252–5.CrossRefPubMed

74.

Ringe JD, Dorst A, Faber H, Ibach K. Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int. 2004;24(2):110–3. doi:10.1007/s00296-003-0388-y.CrossRefPubMed

75.

Sawka AM, Papaioannou A, Adachi JD, Gafni A, Hanley DA, Thabane L. Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord. 2005;6:39. doi:10.1186/1471-2474-6-39.PubMedCentralCrossRefPubMed

76.

Ringe JD, Farahmand P, Faber H, Dorst A. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study. Rheumatol Int. 2009;29(3):311–5. doi:10.1007/s00296-008-0689-2.CrossRefPubMed

77.

Ringe JD, Faber H, Farahmand P, Dorst A. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int. 2006;26(5):427–31. doi:10.1007/s00296-005-0004-4.CrossRefPubMed

78.

Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res. 2009;24(4):719–25. doi:10.1359/jbmr.081214.CrossRefPubMed

79.••

Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl B, et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med. 2012;367(18):1714–23. doi:10.1056/NEJMoa1204061. This randomized clinical trial demonstrated significant reduction of radiographic vertebral fracture in older men with osteoporosis treated with zoledronic acid. This was the first clinical trial of men that used fracture as the primary endpoint.CrossRefPubMed

80.••

Ensrud KE, Taylor BC, Peters KW, Gourlay ML, Donaldson MG, Leslie WD, et al. Implications of expanding indications for drug treatment to prevent fracture in older men in United States: cross sectional and longitudinal analysis of prospective cohort study. BMJ. 2014;349:g4120. doi:10.1136/bmj.g4120. This observational study demonstrated that different choices of the definition of osteoporosis in men had major effects on the proportion of men identified as candidates for antifracture treatment. The prevalence of hip and major osteoporotic fracture by each definition suggested that men with osteoporosis by WHO diagnostic criteria are most likely to benefit from treatment.PubMedCentralCrossRefPubMed

81.

Lewiecki E, Gordon C, Baim S, Leonard M, Bishop N, Bianchi M, et al. International Society for Clinical Densitometry 2007 adult and pediatric official positions. Bone. 2008;43:1115–21.CrossRefPubMed

82.

Liu H, Paige NM, Goldzweig CL, Wong E, Zhou A, Suttorp MJ, et al. Screening for osteoporosis in men: a systematic review for an American College of Physicians guideline. Ann Intern Med. 2008;148(9):685–701.CrossRefPubMed

83.

Qaseem A, Snow V, Shekelle P, Hopkins Jr R, Forciea MA, Owens DK. Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008;148(9):680–4.CrossRefPubMed

Title: Bone Density Screening and Re-screening in Postmenopausal Women and Older Men
Authors: Margaret L. Gourlay
Robert A. Overman
Kristine E. Ensrud
Publication date: 01-12-2015
Publisher: Springer US
Published in: Current Osteoporosis Reports / Issue 6/2015
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI: https://doi.org/10.1007/s11914-015-0289-5

At a glance: The STEP trials

Springer Medicine

Bone Density Screening and Re-screening in Postmenopausal Women and Older Men

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2015

Pathophysiology of Vascular Calcification

A Mechanism-Based Approach to the Management of Osteoarthritis Pain

Prebiotic and Probiotic Regulation of Bone Health: Role of the Intestine and its Microbiome

How Long to Treat with Denosumab

Articular Cartilage: Structural and Developmental Intricacies and Questions

Vibration Therapy to Prevent Bone Loss and Falls: Mechanisms and Efficacy